A β-mercaptoethanol–modified enzyme-linked immunosorbent assay for diagnosis of canine visceral leishmaniasis

Laura Barral-Veloso
Saul J. Semião-Santos
Paulo P. de Andrade
Marcia A. de Melo
Luís Martins
Artur A. Marinho
José A. A. de Almeida
Luís Cardoso
Abdallah el Harith

Center for Diagnosis and Research in Leishmaniasis, Institute of Agrarian and Environmental Mediterranean Sciences (Barral-Veloso, Semião-Santos), University of Évora, Évora, Portugal
Department of Veterinary Medicine (Martins, Marinho), University of Évora, Évora, Portugal
Department of Animal Science (de Almeida), University of Évora, Évora, Portugal
Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences, University of Trás-os-Montes e Alto Douro, Vila Real, Portugal (Cardoso)
Department of Genetics, Center of Biological Sciences, Federal University of Pernambuco, Recife, Pernambuco, Brazil (de Andrade)
Laboratory of Molecular Genetics and Immunology, Center for Rural Health and Technology, Federal University of Campina Grande, Patos, Paraíba, Brazil (de Melo)
Dutch Ministry of Foreign Affairs/Mission to Ahfad University for Women, Omdurman, Sudan (el Harith)

Abstract

Two immunoglobulin G enzyme-linked immunosorbent assay (ELISA) versions using whole promastigotes of Leishmania infantum (syn. Leishmania chagasi) treated either with β-mercaptoethanol (β-ME-ELISA) or trypsin (TRYP-ELISA) as antigens were developed for the diagnosis of canine visceral leishmaniasis (CVL). By comparison with the direct agglutination test (DAT; 100%, 31/31; 95% confidence interval [CI]: 86.3–100%), slightly lower sensitivity was demonstrated for the newly developed β-ME-ELISA (93.5%, 29/31; 95% CI: 77.2–98.9%). Sensitivity was higher for β-ME-ELISA compared with TRYP-ELISA (87.1%, 27/31; 95% CI: 69.2–95.8%) in serum samples from dogs with CVL. When tested with sera from 37 healthy dogs and from 45 dogs with clinical conditions other than CVL, a specificity of 97.6% (80/82; 95% CI: 90.1–99.6%) was estimated for β-ME-ELISA as compared to 100% (82/82; 95% CI: 94.4–100%) and 95.1% (78/82; 95% CI: 87.3–98.4%) for DAT and TRYP-ELISA, respectively. Observed agreement was 94.0% (95% CI: 88.7–97.1%) between DAT and β-ME-ELISA (κ = 0.879; 95% CI: 0.803–0.956) and 87.4% (95% CI: 80.8–92.1%) between DAT and TRYP-ELISA (κ = 0.743; 95% CI: 0.636–0.851). Current results advocate application of the new β-ME-ELISA for diagnosis of CVL at the laboratory level and confirmation of results obtained with the DAT in field studies.